Across TCGA pan-cancer cohorts, HDDC2 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated HDDC2 data layer compared with 25 for mass-spec protein and 6 for mass-spec protein.
The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher HDDC2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated HDDC2 expression acts as an unfavorable survival marker.
UCEC and SKCM are the cancer types where HDDC2 Mutation most reproducibly stratifies survival.